Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Revolution Medicines is seeking a Vice President of Disease Area Franchise Head to lead clinical development for RAS-addicted cancers. The role involves overseeing clinical science teams, guiding clinical strategy, interfacing with regulatory authorities, and ensuring the company's success in the market. This position requires strategic thinking and leadership in a rapidly evolving industry.
Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.